230 related articles for article (PubMed ID: 12492613)
1. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Wanwimolruk S; Paine MF; Pusek SN; Watkins PB
Br J Clin Pharmacol; 2002 Dec; 54(6):643-51. PubMed ID: 12492613
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and elimination of quinine in healthy volunteers.
Mirghani RA; Hellgren U; Bertilsson L; Gustafsson LL; Ericsson O
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):423-7. PubMed ID: 12920491
[TBL] [Abstract][Full Text] [Related]
4. Grapefruit juice has no effect on quinine pharmacokinetics.
Ho PC; Chalcroft SC; Coville PF; Wanwimolruk S
Eur J Clin Pharmacol; 1999 Jul; 55(5):393-8. PubMed ID: 10456490
[TBL] [Abstract][Full Text] [Related]
5. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
6. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.
Mirghani RA; Hellgren U; Westerberg PA; Ericsson O; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1999 Nov; 66(5):454-60. PubMed ID: 10579472
[TBL] [Abstract][Full Text] [Related]
7. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.
Mirghani RA; Ericsson O; Tybring G; Gustafsson LL; Bertilsson L
Eur J Clin Pharmacol; 2003 May; 59(1):23-8. PubMed ID: 12743670
[TBL] [Abstract][Full Text] [Related]
8. Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.
Mirghani RA; Yasar U; Zheng T; Cook JM; Gustafsson LL; Tybring G; Ericsson O
Drug Metab Dispos; 2002 Dec; 30(12):1368-71. PubMed ID: 12433805
[TBL] [Abstract][Full Text] [Related]
9. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
10. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
11. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Chaipol P; Sunbhanich M
J Pharm Pharmacol; 2000 Oct; 52(10):1265-9. PubMed ID: 11092571
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
13. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.
Soyinka JO; Onyeji CO; Omoruyi SI; Owolabi AR; Sarma PV; Cook JM
J Pharm Pharmacol; 2009 Apr; 61(4):439-43. PubMed ID: 19298689
[TBL] [Abstract][Full Text] [Related]
14. Quinine pharmacokinetics in chronic haemodialysis patients.
Roy L; Bannon P; Villeneuve JP;
Br J Clin Pharmacol; 2002 Dec; 54(6):604-9. PubMed ID: 12492607
[TBL] [Abstract][Full Text] [Related]
15. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
16. Oral quinine pharmacokinetics and dietary salt intake.
Newton P; Simpson A; Wanwimolruk S; Maliakal P; Villegas L; Kuypers D; White NJ
Eur J Clin Pharmacol; 2001 May; 57(2):111-3. PubMed ID: 11417441
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
18. Effects of cigarette smoking on quinine pharmacokinetics in malaria.
Pukrittayakamee S; Pitisuttithum P; Zhang H; Jantra A; Wanwimolruk S; White NJ
Eur J Clin Pharmacol; 2002 Aug; 58(5):315-9. PubMed ID: 12185554
[TBL] [Abstract][Full Text] [Related]
19. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
20. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Zhao XJ; Ishizaki T
Br J Clin Pharmacol; 1997 Nov; 44(5):505-11. PubMed ID: 9384469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
